InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (13 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
13
T+90 hit rate
9%
T+90 mean return
-31.6%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Conroy Kevin T, Chief Executive Officer and Chairman of the Board. Director active across 6 companies, notably Exact Sciences CORP. Cumulatively, 66 disclosures have been recorded. Breakdown: 1 buy · 13 sells. Total volume traded: €17.3m. History available since 30 April 2021. The latest transaction was filed on 20 May 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations66 total
1,745 shares0Common StockSEC:0001193125-26-237321:0
2,286 shares0Common shares without par valueSEC:0001306119-26-000004:0
1,148 shares0Common StockSEC:0001415889-25-014232:0
66,723 shares@ US$22.386.3% of flowCommon StockSEC:0000950170-25-036484:0
18,143 shares0Common StockSEC:0000950170-25-032293:0
13,180 shares0Common StockSEC:0000950170-25-028163:0
10,374 shares0Common StockSEC:0000950170-25-024896:0
19,500 shares@ US$51.354.3% of flowCommon StockSEC:0000950170-24-126119:0
Ideal exit: 10 Aug 2025 (T+270)
660 shares0Common StockSEC:0001415889-24-014460:0
2,489 shares0Common StockSEC:0000950170-24-052390:0
18,143 shares0Common StockSEC:0001209191-24-004236:0
13,181 shares0Common StockSEC:0001209191-24-004078:0
102,837 shares@ US$13.966.0% of flowCommon StockSEC:0001209191-24-003944:0
23,238 shares0Common StockSEC:0001209191-24-003918:0
10,374 shares0Common StockSEC:0001209191-24-003867:0
709 shares@ US$30.020.1% of flowCommon StockSEC:0001209191-24-003463:0
14,775 shares0Common StockSEC:0001062993-23-006332:0
13,180 shares0Common StockSEC:0001209191-23-014239:0
10,374 shares0Common StockSEC:0001209191-23-012207:0
31,132 shares0Common StockSEC:0001209191-23-010133:0
9,705 shares0Common StockSEC:0001209191-23-009301:0
53,324 sharesCommon Stock, par value $0.0001SEC:0000899243-22-028873:0
328 shares@ US$47.410.1% of flowCommon StockSEC:0001209191-22-041081:0
10,204 shares@ US$1.4713.6% of flowCommon Stock, par value $0.0001SEC:0000899243-22-025011:0
8,994 shares0Common Stock, par value $0.0001SEC:0000899243-22-018826:0
25 of 66 declarations
About Conroy Kevin T
Kevin T. Conroy is best known as the Chief Executive Officer and Chairman of the Board of Exact Sciences Corp., where he has served in senior leadership since 2009 and as Chairman since 2014. His career has been built in the molecular diagnostics, healthcare technology, and life sciences sectors, with more than two decades of experience spanning legal, strategic, and executive leadership roles. Prior to Exact Sciences, he served as President and Chief Executive Officer of Third Wave Technologies, and earlier as General Counsel of the same company, giving him deep experience at the intersection of innovation, regulation, and commercialization. He also worked at GE Healthcare as intellectual property counsel, further strengthening his foundation in healthcare technology and corporate strategy. At Exact Sciences, Conroy has been closely associated with the company’s evolution into a leading cancer diagnostics business. His leadership has covered a period of sustained growth, including the development, regulatory approval, and commercialization of diagnostic tests, as well as the buildout of a high-performing organizational culture. His profile reflects a blend of executive leadership, corporate strategy, finance, M&A insight, and governance experience, which is particularly relevant in highly regulated healthcare and biotechnology markets. Beyond Exact Sciences, he has served on the boards of several public or public-market-adjacent life sciences companies, including Adaptive Biotechnologies Corp., Epizyme, Inc., and SomaLogic, Inc. These board roles indicate that he has been valued for strategic oversight and sector expertise across biotech and diagnostics businesses. In those settings, his contributions have generally centered on governance, growth strategy, and helping management teams navigate commercialization and value creation. Overall, Kevin T. Conroy stands out as a seasoned U.S. biotech executive whose career has been defined by building and scaling diagnostics platforms, leading through regulatory and commercial milestones, and supporting innovation-driven healthcare companies.
